Cargando…
Mass spectrometry quantifies target engagement for a KRASG12C inhibitor in FFPE tumor tissue
BACKGROUND: Quantification of drug-target binding is critical for confirming that drugs reach their intended protein targets, understanding the mechanism of action, and interpreting dose-response relationships. For covalent inhibitors, target engagement can be inferred by free target levels before a...
Autores principales: | Chambers, Andrew G., Chain, David C., Sweet, Steve M., Song, Zifeng, Martin, Philip L., Ellis, Matthew J., Rooney, Claire, Kim, Yeoun Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599008/ https://www.ncbi.nlm.nih.gov/pubmed/37880622 http://dx.doi.org/10.1186/s12014-023-09435-8 |
Ejemplares similares
-
The addition of FAIMS increases targeted proteomics sensitivity from FFPE tumor biopsies
por: Sweet, Steve, et al.
Publicado: (2022) -
KRasG12C inhibitors in clinical trials: a short historical perspective
por: Goebel, Lisa, et al.
Publicado: (2020) -
Role and regulation of Yap in KrasG12D-induced lung cancer
por: Mao, Yaopan, et al.
Publicado: (2017) -
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
por: Macaya, Irati, et al.
Publicado: (2023) -
Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors
por: Goebel, Lisa, et al.
Publicado: (2023)